- Newly published clinical data show good results seven years after prostate cancer treatment with focused ultrasound.
- The multisite study of 1,379 men in the UK with nonmetastatic prostate cancer was published in European Urology.
- After seven years, all treated patients were metastasis-free, and none died from prostate cancer.
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1,379 Men with Nonmetastatic Prostate Cancer: A Multi-Institute 15-year Experience
Newly published clinical data conducted by a large group of collaborative researchers show good midterm (seven year) results after prostate cancer treatment with high-intensity focused ultrasound (HIFU). The multisite (13-center) study of 1,379 men in the United Kingdom with nonmetastatic prostate cancer was published in the journal European Urology. After seven years, all treated patients were metastasis-free, none died from prostate cancer, and failure-free survival in intermediate- and high-risk cancers was 68% and 65%, respectively. Adverse events occurred in 0.5% of the patients. Data were collected in the HIFU Evaluation and Assessment of Treatment (HEAT) registry during the 15-year period from 2005 through 2020, and five or more years of follow-up data were available for 325 (24%) patients. The authors concluded that focal HIFU provided good medium-term cancer control in carefully selected patients with clinically significant prostate cancer. Patients can be told that focal HIFU treatment to the areas of the prostate with cancer can provide an alternative to treating the whole prostate gland. HIFU provides good results up to seven years after treatment.